Abstract
Menstrual suppression (the use of hormonal contraceptive methods to eliminate or significantly
decrease the frequency of menstrual cycles) is frequently used in the adolescent population
for the management of menstrual symptoms such as heavy or painful periods, premenstrual
syndrome, menstrual migraines, or even for patient preference. However, in cases of
menstrual suppression in special populations additional risks and benefits need to
be considered. The purpose of this article is to review the options and medical considerations
for menstrual suppression in patients undergoing chemotherapy who might be at risk
of abnormal uterine bleeding, those with intellectual or physical disability, and
transgender and gender nonbinary individuals.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Pediatric and Adolescent GynecologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Menstrual suppression: current perspectives.Int J Womens Health. 2014; 6: 631
- Continuous use of oral contraceptives: an overview of effects and side-effects.Acta Obstet Gynecol Scand. 2013; 92: 125
- Long-cycle treatment with oral contraceptives.Drugs. 2004; 64: 2447
- Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.Contraception. 2009; 80: 504
- Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive.Obstet Gynecol. 2013; 122: 601
- 20 μg versus >20 μg estrogen combined oral contraceptives for contraception.Cochrane Database Syst Rev. 2013; 8: CD003989
- Oral contraceptive use and bone density in adolescent and young adult women.Contraception. 2010; 81: 35
- Low-dose combined oral contraceptive use is associated with lower bone mineral content variation in adolescents over a 1-year period.BMC Endocr Disord. 2015; 15: 15
- Extended regimens of the contraceptive vaginal ring: a randomized trial.Obstet Gynecol. 2005; 106: 473
- Extended regimens of the vaginal contraceptive ring: cycle control.Contraception. 2009; 80: 430
- Bleeding patterns of women using extended regimens of the contraceptive vaginal ring.Contraception. 2007; 75: 204
- Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial.Obstet Gynecol. 2005; 105: 1389
- Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons.Contraception. 2009; 80: 113
- Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg.Contraception. 2006; 74: 234
- Levonorgestrel-releasing intrauterine device use in female adolescents with heavy menstrual bleeding and bleeding disorders: single institution review.J Pediatr Adolesc Gynecol. 2017; 30: 479
- Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use.Acta Obstet Gynecol Scand. 1999; 78: 716
- Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years.Contraception. 2002; 65: 129
- Levonorgestrel-releasing intra-uterine systems as female contraceptives.Expert Opin Pharmacother. 2018; 19: 677
- Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.Expert Rev Clin Pharmacol. 2017; 10: 833
- LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years.Expert Opin Drug Deliv. 2017; 14: 1131
- Liletta (levonorgestrel-releasing intrauterine system) [package insert]. Actavis Pharma, Inc, Parsippany, NJ2015
- A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.Fertil Steril. 2012; 97: 616.e1
- Kyleena (levonorgestrel-releasing intrauterine system (19.5) [product monograph]). Bayer Inc, Whippany, NJ2018
- Menstrual suppression for adolescents.Curr Opin Obstet Gynecol. 2014; 26: 323
- Inducement of therapeutic amenorrhea in mentally retarded women: two-year follow-up study.Am J Ment Defic. 1986; 90: 591
- Clinical experience with the progestogen-only pill.Contraception. 1990; 42: 489
- Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation.Bone Marrow Transplant. 1998; 21: 821
- Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate [erratum in 2007; 110:936].Cancer. 2006; 107: 1634
- Inducing amenorrhea during bone marrow transplantation. A pilot study of leuprolide acetate.J Reprod Med. 1997; 42: 537
- Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study.Leuk Lymphoma. 2001; 42: 1033
- Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.Obstet Gynecol. 2002; 99: 709
- Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis: a randomized controlled trial.Obstet Gynecol. 2015; 126: 617
- The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.Reprod Sci. 2012; 19: 563
- American college of obstetrics and gynecology committee on adolescent health care: ACOG committee opinion No. 668. Menstrual manipulation for adolescents with physical and developmental disabilities.Obstet Gynecol. 2016; 128: e20
- Menstrual suppression in special circumstances.J Obstet Gynaecol Can. 2014; 36: 915
- Menstrual and contraceptive management in women with intellectual disability.Med J Aust. 2002; 176: 108
- Child sexual abuse revictimization: child demographics, familial psychosocial factors, and sexual abuse case characteristics.J Forensic Nurs. 2016; 12: 151
- Thyroid dysfunction in patients with Down syndrome: results from a multi-institutional registry study.Am J Med Genet A. 2017; 173: 1539
- Medication-induced hyperprolactinemia.Mayo Clin Proc. 2005; 80: 1050
- Interactions between hormonal contraception and antiepileptic drugs: clinical and mechanistic considerations.Seizure. 2015; 28: 66
- Effect of antiepileptic drugs on oral contraceptives.Am Fam Physician. 2008; 78: 634
- Transdermal delivery of combined hormonal contraception: a review of the current literature.Int J Womens Health. 2017; 9: 315
- Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study.Fertil Steril. 2008; 90: 2060
- Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.Arch Pediatr Adolesc Med. 2005; 159: 139
- American College of Obstetrics and Gynecology Committee on Adolescent Health Care: ACOG Committee Opinion No. 602. Depot medroxyprogesterone acetate and bone effects.Obstet Gynecol. 2014; 123: 1398
- Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate.Obstet Gynecol. 2011; 117: 793
- Women with epilepsy initiating a progestin IUD: a prospective pilot study of safety and acceptability.Epilepsia. 2016; 57: 1843
- A pilot study of levonorgestrel concentrations and bleeding patterns in women with epilepsy using a levonorgestrel IUD and treated with antiepileptic drugs.Contraception. 2019; 99: 251
- Long-term complications of endometrial ablation: cause diagnosis, treatment and prevention.J Minim Invasive Gynecol. 2007; 14: 399
- Pregnancy outcomes after endometrial ablation in a multi-institutional cohort.Am J Perinatol. 2018; 35: 931
- Pregnancy after endometrial ablation: a systematic review.BJOG. 2018; 125: 43
- American College of Obstetrics and Gynecology Committee on Adolescent Health Care: ACOG Committee Opinion No. 606. Options for prevention and management of heavy menstrual bleeding in adolescent patients undergoing cancer treatment.Obstet Gynecol. 2014; 124: 397
- SEER Cancer Statistics Review, 1975-2010.National Cancer Institute, Bethesda, MD2013
- The management of menstrual suppression and uterine bleeding: a survey of current practices in the Pediatric Blood and Marrow Transplant Consortium.Pediatr Blood Cancer. 2012; 59: 553
- Fertility preservation in patients with cancer: ASCO clinical practice guideline update.J Clin Oncol. 2018; 36: 1994
- GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.Hum Reprod. 2015; 30: 2912
- Protecting effects of gonadotropin-releasing hormone agonist on chemotherapy-induced ovarian damage in premenopausal breast cancer patients: a systematic review and meta-analysis.Breast Care (Basel). 2017; 12: 48
- Gonadotrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial.Obstet Gynecol. 2013; 121: 78
- Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation.Blood. 1998; 92: 4568
- Hormonal therapy after stem cell transplantation and risk of veno-occlusive disease.Blood. 1999; 93: 3154
- Epidemiology of cancer-related venous thromboembolism.Best Pract Res Clin Haematol. 2009; 22: 9
- US medical eligibility criteria for contraceptive use, 2016.MMWR Recomm Rep. 2016; 65: 1
- Treatment of menorrhagia in women undergoing hematopoietic stem cell transplant.Bone Marrow Transplant. 2004; 34: 363
- Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.Cochrane Database Systematic Rev. 2005; 4: CD002126
- Continuation of a levonorgestrel intrauterine device during hematopoietic stem cell transplant: a case report.Anticancer Res. 2017; 37: 1985
- Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline.Endocr Pract. 2017; 23: 1437
- Queer periods: attitudes toward and experiences with menstruation in the masculine of centre and transgender community.Cult Health Sex. 2016; 18: 1238
- Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder.Endocr J. 2013; 60: 275
- The response of the menstrual cycle to initiation of hormonal therapy in transgender men.Transgend Health. 2017; 2: 176
- Effects of cross-sex hormone treatment on transgender women and men.Obstet Gynecol. 2015; 125: 605
- Effects of three different testosterone formulations in female-to-male transsexual persons.J Sex Med. 2014; 11: 3002
- Transgender men who experienced pregnancy after female-to-male gender transitioning.Obstet Gynecol. 2014; 124: 1120
- Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series.Am J Obstet Gynecol. 2019; 220: 257.e1
Article info
Publication history
Published online: April 10, 2019
Footnotes
Both authors have no conflict of interest to disclose.
This article is published as part of a supplement supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc. This, and the other articles in this supplement, have been reviewed using the same criteria as that applied to all Journal of Pediatric and Adolescent Gynecology submissions.
Identification
Copyright
© 2019 Published by Elsevier Inc. on behalf of North American Society for Pediatric and Adolescent Gynecology.
